New antibiotics are needed to combat rising levels of resistance, with new Mycobacterium tuberculosis (Mtb) drugs having the highest priority. However, conventional whole-cell and biochemical antibiotic screens have failed. Here we develop a strategy termed PROSPECT (primary screening of strains to prioritize expanded chemistry and targets), in which we screen compounds against pools of strains depleted of essential bacterial targets. We engineered strains that target 474 essential Mtb genes and screened pools of 100-150 strains against activity-enriched and unbiased compound libraries, probing more than 8.5 million chemical-genetic interactions. Primary screens identified over tenfold more hits than screening wild-type Mtb alone, with chemical-genetic interactions providing immediate, direct target insights. We identified over 40 compounds that target DNA gyrase, the cell wall, tryptophan, folate biosynthesis and RNA polymerase, as well as inhibitors that target EfpA. Chemical optimization yielded EfpA inhibitors with potent wildtype activity, thus demonstrating the ability of PROSPECT to yield inhibitors against targets that would have eluded conventional drug discovery.
The WHO (World Health Organization) 1 has declared antibiotic resistance one of the greatest threats to health, with tuberculosis in particular causing more than 1.6 million deaths every year 2 . Despite the recent approval of two new drugs 3, 4 , tuberculosis drug discovery has not kept pace with increasing levels of drug resistance 5 . A fundamental challenge in antibiotic discovery is finding new compound classes that kill the causative pathogen, especially by inhibiting essential targets without host toxicity. Primary chemical screening approaches using biochemical, target-based assays have yielded compounds that lack whole-cell activity, and hit compounds derived from conventional whole-cell assays using wild-type bacteria make it difficult to determine the mechanism of action (MOA), thus delaying compound prioritization and progression. The all-too-few successful cases for Mtb, the causative agent of tuberculosis, underscore this challenge, with hit compounds repeatedly targeting two proteins (MmpL3 and DprE1), leaving most of the approximately 625 essential proteins of Mtb unexploited [6] [7] [8] . We aimed to develop an antimicrobial discovery paradigm that simultaneously identifies whole-cell active compounds and predicts their MOA from the primary screening data, thereby incorporating putative target information into hit prioritization. This strategy enables the exploration of broader target space and the discovery of new chemical scaffolds that could not be identified by conventional whole-cell screening. We performed primary chemical screening with hundreds of mutant strains that were depleted in essential targets (known as hypomorphs), and exploit their hypersensitivity to generate large-scale chemical-genetic interaction profiles (CGIPs). Although such drug hypersensitivity is well established in yeast [9] [10] [11] , depletion of essential targets of haploid bacteria is challenging. Consequently, chemical screening of bacterial hypomorphs has been limited to a single hypomorph of Staphylococcus aureus 12 and Mtb 13, 14 , or to determining the MOA of a single compound against small collections of S. aureus hypomorphs 15, 16 or a genome-wide non-essential gene-deletion library in Escherichia coli 17 . By contrast, generating CGIPs by screening large hypomorph pools (100-150 hypomorphs) against large chemical libraries (50,000 compounds)-an approach we term PROSPECT (primary screening of strains to prioritize expanded chemistry and targets)-markedly increases the detection of active compounds and allows immediate target annotation, informing hit prioritization.
PROSPECT yielded tenfold more hit compounds, each associated with CGIPs, than conventional whole-cell screening approaches. Using primary CGIPs, we rapidly identified and validated more than 40 new scaffolds against established targets including DNA gyrase, RNA polymerase (RNAP), and the biosynthesis of the cell wall, folate and tryptophan. We also discovered an inhibitor of a new target-the essential efflux pump EfpA. Because hits may have limited activity
Article reSeArcH against wild-type bacteria, we demonstrated the ability to optimize the EfpA inhibitor to drug-like potency against wild-type Mtb. PROSPECT thus uncovers molecules against new targets with potent wild-type activity that could not have been found by conventional screening.
Large-scale CGIPs from primary screening
We genetically engineered hypomorphs by controlling target levels using conditional proteolysis 18, 19 or transcriptional control. For proteolytic control, essential genes were fused to a C-terminal tag, which targets the protein for degradation (Extended Data Fig. 1a) . We recognized that some proteins may not be amenable to this strategy because the tag disrupts function or is destabilizing enough to prohibit viability. To control the level of target depletion, we attempted to construct for each gene up to five hypomorphs, with varying degrees of knockdown (Extended Data Fig. 1b, c) . At the time of publication, we have constructed 2,014 strains representing the first 474 of approximately 625 essential genes defined in Mtb 20 (Supplementary Data 1), each carrying a 20-nucleotide barcode with conserved flanking regions.
We established a multiplexed assay to measure the abundance of each strain in a pool by amplifying and sequencing strain barcodes [21] [22] [23] [24] (Extended Data Fig. 1d, e) . By creating strain mixtures with abundances that span three orders of magnitude, we confirmed that sequencing read counts of the barcodes were an accurate and reproducible proxy for abundance (Fig. 1a) . Using this assay to determine the fitness of each strain in a pool containing 100-150 strains, including barcoded wild-type strain in 384-well plates over two weeks, we selected a single mutant for each gene that corresponds to the greatest degradation of the essential target while maintaining similar growth to the wild-type strain (Extended Data Fig. 2a) for inclusion in the final screening pool; this balanced the need for reliable strain behaviour and increased the likelihood of finding hypersensitized strain inhibitors. We anticipated that we would not discover inhibitors for some hypomorphs in which the achieved degree of target depletion does not confer strain hypersensitivity, or because their slower growth resulted in lower statistical power. Nevertheless, using our defined screening pool and rifampin as a positive control, we observed excellent assay performance across the dynamic range for all strains (Zʹ factors > 0.5; Extended Data Fig. 2b) .
Finally, we developed a barcode counting (ConCensusMap) and inference (ConCensusGLM) computational pipeline that calculated the fold change (that is, log 2 (abundance relative to control)) of strain abundance after compound exposure compared with dimethylsulfoxide (DMSO) control and the associated P value. The fold change vector across all strains for a compound is termed the CGIP.
Genetic interactions of Mtb-bioactive compounds
We assembled a library of 3,226 bioactive small molecules, enriched for compounds with activity against wild-type Mtb based on literature reports (Extended Data Fig. 2c ; see Methods), confirmed their activity by testing for inhibition of green fluorescent protein (GFP)-expressing wild-type Mtb, and found that 1,312 (45%) had an MIC 90 value (the minimum inhibitory concentration required to inhibit growth by 90% of its maximal rate) of less than 64 µM (Extended Data Fig. 2d ). We then screened this chemical library at 1.1, 3.3, 10 and 30 µM against a pool of the first 100 successfully created Mtb hypomorphs in duplicate (Pearson's r = 0.93), generating 1,290,400 potential chemical-genetic interactions.
Most interactions (927,025, 71%) were inhibitory (fold change < 1) (Extended Data Fig. 2e ); of these, 55,508 interactions (6%) representing 940 compounds (29%) were strong (P < 10
−10
). In a minority, protein depletion conferred resistance to inhibitors of wild-type Mtb; for example, the mycothiol cysteine ligase (MshC) hypomorph was resistant to tuberculosis drugs isoniazid (INH) and ethionamide (ETH), known inhibitors of enoyl-[acyl-carrier-protein] reductase (InhA) 25 .
Using an orthogonal simplex growth assay, we retested 112 identified hits that displayed some specificity (activity against less than 10 strains) for a subset of mutants (P < 10 −10 ) against their corresponding hypomorph interactor, wild-type Mtb, and several other hypomorphs as negative controls. Using a receiver operating characteristic (ROC) curve to assess the ability of the multiplexed assay to predict activity in the orthogonal assay, the area under the ROC curve (AUROC; 0.74) indicated a high true-positive rate in the primary assay with a wellcontrolled false-positive rate (Fig. 1b) . Given the complexity of the primary screen, reassuringly 1,375 (52%) of the 2,664 strong interactions were confirmed in the secondary assay.
We recovered interactions between well-characterized inhibitors and hypomorphs of established targets (Fig. 1c) , including between the fluoroquinolones and the DNA gyrase α-subunit (GyrA), rifampin and the RNAP β-subunit (RpoB), and BRD-4592 and the tryptophan Article reSeArcH synthase α-subunit (TrpA) 26 . Notably, trimethoprim (TMP)-a folate biosynthesis inhibitor that targets dihydrofolate reductase (DHFR)-demonstrated a strong interaction with the folate pathway enzyme glutamine amidotransferase (TrpG) rather than DHFR. Although the DHFR hypomorph demonstrated hypersensitization to TMP when tested in isolation (Extended Data Fig. 1f ), its slow growth provided low statistical power in primary screening. By contrast, the ThyA hypomorph was resistant to TMP, consistent with the previous observation that DHFR is non-essential on ThyA loss-of-function 27 . Projecting the 400-dimensional CGIPs (100 strains × 4 concentrations) for each compound onto two dimensions, we found that compounds with the same MOA clustered together, independent of their chemical structures (Fig. 2) .
New inhibitor classes of validated targets
We sought new compound scaffolds that inhibited well-validated, clinical targets based solely on primary screening data by training on a reference ground-truth set of 107 CGIPs of known antimicrobials (Supplementary Data 2). Using Lasso classification models 28 -a supervised machine learning method-we identified 39 new inhibitors of DNA gyrase (training set n = 14) and of the biosynthesis of mycolic acid (n = 6), folate (n = 12) and tryptophan.
DNA gyrase inhibitors
Training on CGIPs of the fluoroquinolones, our model identified hypersensitivity of the GyrA hypomorph as the most discriminatory feature of gyrase inhibition, which we term a sentinel strain (Extended Data Fig. 3a) . The model predicted 55 non-quinolone DNA gyrase inhibitors (Fig. 3a) , including the structurally distinct inhibitor novobiocin.
Using a Mtb DNA gyrase in vitro assay, we confirmed 27 (52%) out of 52 predicted new DNA gyrase inhibitors (Extended Data Fig. 4a ), whereas 25 randomly selected compounds showed no activity (classifier enrichment P = 2 × 10 −7 , Fisher's exact test; AUROC = 0.89). Of the validated compounds, tryptanthrin (Extended Data Fig. 4b ) is an anti-infective with a target that has eluded extensive antibacterial and antitrypanosomal research, with current results suggesting that it may be a gyrase inhibitor 29, 30 . Furthermore, the acridine scaffold of ethacridine (Fig. 3c ) has been previously reported to inhibit DNA gyrase 31 . All remaining scaffolds were previously undiscovered.
Inhibitors of mycolic acid biosynthesis
The cornerstone clinical antitubercular prodrugs INH and ETH both inhibit InhA 32 -a key enzyme in the biosynthesis of mycolic acid. We sought new inhibitors of mycolic acid biosynthesis by training on CGIPs of these drugs. Although the strain pool did not include an InhA hypomorph, our model successfully used increased relative fitness of the MshC sentinel strain (Fig. 3c, Extended Data Fig. 3b) . MshC catalyses the incorporation of cysteine into mycothiol-an antioxidant unrelated to biosynthesis of mycolic acid-and has been shown to confer resistance to INH and ETH when depleted 25 . The model predicted six hydrazone derivatives of INH that are inactive against a loss-of-function mutant of the catalase KatG, indicating that they require KatG activation in the same way as the INH prodrug 33 . Notably, the model also predicted one completely new scaffold, the indenedione BRD-9942 (Fig. 3d) 
Inhibitors of folate and tryptophan biosynthesis
Folate biosynthesis has been an effective antimicrobial target, although not for Mtb. We sought new folate inhibitor classes by training on the CGIPs of the sulfonamides, which target dihydropteroate synthase. The most discriminatory feature was inhibition of the TrpG sentinel strain (Extended Data Fig. 3c ). TrpG supports the biosynthesis of both folate and tryptophan (Extended Data Fig. 6a ), catalysing the formation of the folate precursor 4-amino-4-deoxychorismate and the tryptophan precursor 2-amino-2-deoxyisochorismate.
We tested whether supplementation with tryptophan, folate or the folate pathway intermediate para-amino benzoic acid (PABA) suppressed the activity of 7 of the 43 predicted compounds that had wild-type Mtb activity and spanned several chemotypes (Fig. 3e, f) . The effects of the nitrothiophene compounds BRD-2550, BRD-3387, BRD-5592 and BRD-9737 (Fig. 3f , Extended Data Fig. 6d ), and a para-aminosalicylic acid (PAS) derivative BRD-9819, were abolished by supplementation with both PABA and folate; this pattern is the same for the known DHFR inhibitors methotrexate and PAS (Extended Data Fig. 6b ). By contrast, BRD-8884 had effects that could only be rescued by folate and not by PABA (Extended Data Fig. 6c ), suggesting a new folate target. Thus, PROSPECT uncovered inhibitors that target several different steps in the folate pathway.
Finally, the effects of BRD-7721-a 3-indolepropionic acid (3-IPA) ester-were only abrogated by supplementation with tryptophan (Extended Data Fig. 6c ), suggesting that tryptophan biosynthesis is its target. 3-Indolepropionic acid was recently identified as having antimycobacterial activity in a fragment-based screen 34, 35 and its activity was also abolished by supplementation with tryptophan (Extended Data Fig. 6b ).
Empirical validation of new folate and tryptophan inhibitors allowed retraining of updated models for each pathway. The refined classifier learned to weigh FolB hypomorph behaviour in conjunction with TrpG in its discrimination of folate inhibitors (Extended Data Fig. 3d , e).
Screening a larger, unbiased compound library
We applied the PROSPECT approach to a large, unbiased library of approximately 50,000 compounds at 50 µM and an expanded pool of 152 strains available at the initiation of this screen, to demonstrate the scalability of the model and its ability to identify compounds with potential activity against wild-type Mtb that could be revealed by hypersensitive hypomorphs and to discover inhibitors of new targets, which, after chemical optimization, could have potent wild-type activity. 45 . DHPS, dihydropteroate synthase. Grey circles represent compounds, and coloured circles represent a subset of compounds with known MOAs. Representative CGIPs are shown for compounds that represent each of the four exemplary MOAs (n = 2 biologically independent experiments). Profiles show the mean fold change (that is, log 2 (abundance relative to DMSO control)) of each strain at each concentration tested, with wild-type Mtb in dark grey, and mutants of interest highlighted.
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Of the 7,245,009 potential chemical-genetic interactions tested, 95,685 (1.3%) were strongly inhibitory. By selecting 1,331 compounds for retesting, we confirmed 78% of the inhibitory chemical-genetic interactions (fold change < 1), resulting in an AUROC of 0.74, similar to that observed for the bioactive screen. In an orthogonal assay, the AUROC was 0.69 using 75% inhibition as the ground-truth assumption of true activity (Extended Data Fig. 7a ).
The hit rate against wild-type Mtb alone was 0.9% (436 compounds), which is typical for an unbiased whole-cell compound screen; by contrast, tenfold more compounds (4,403; 9%) were active against at least one of the 152 hypomorph strains (Extended Data Fig. 7b ). In addition, 92 of the 152 hypomorphs had the lowest abundance relative to DMSO control for at least three compounds, suggesting latent diversity in the MOA that is inaccessible by conventional screening. Of the 4,403 active compounds, 3,967 had no activity against wild-type Mtb. However, 73% were highly specific against the hypomorphs (1-10 strains hit) and 16% were relatively non-specific (more than 50 strains hit; these latter compounds will be retested at lower concentrations to delineate their MOAs because wild-type activity is advantageous as a chemical optimization starting point); compounds showed greater strain specificity than the compounds in the bioactive library (35% and 34%), probably because the smaller library is enriched for compounds with wild-type Mtb activity (Extended Data Fig. 7c ). The larger library yielded a greater diversity of CGIPs, suggesting greater target diversity. Clustering of the CGIPs produced 1,864 distinct clusters in the unbiased library compared to 235 in the bioactive library 36 ; unbiased library clusters were meaningful as more than 10% of them were enriched for structurally similar compounds (Extended Data Fig. 7d, e) .
We applied the folate biosynthesis inhibitor classifier derived from training on the bioactive library to data from the unbiased library. Despite being trained on a dataset generated from several concentrations of each compound and a smaller hypomorph set, the folate model showed excellent transferability, predicting 60 compounds from this larger screen (Fig. 4a) , including 12 sulfonamides, 1 PAS derivative, and 2 nitrothiophenes that are now shown to inhibit the folate pathway (Fig. 3f ). Three novel scaffolds (Fig. 4b) had activity that could be suppressed by supplementation with PABA or folate (Extended Data Fig. 7f ). These results demonstrate the scalability and generalizability of the PROSPECT model, and suggest that revealing latent target diversity could allow the discovery of inhibitors of new targets.
Inhibitor discovery without reference data
Having rapidly identified new chemotypes against established targets using reference data, we turned to the discovery of inhibitors with completely new MOAs in the absence of reference data. We developed an approach to identify inhibitors of a target of interest from specific inhibition of the corresponding hypomorph.
Initially, we sought inhibitors of RNAP-a target of the chemotherapyanchoring rifamycins-for which there is increasing resistance. a, Lasso predictor, derived from a DNA gyrase inhibitor classifier applied to the mean fold change (n = 2) values from the bioactive screen, plotted against Tanimoto distance (chemical structure dissimilarity) to the fluoroquinolones, known DNA gyrase inhibitors. Each point is a compound in the screen; those above the horizontal line were predicted DNA gyrase inhibitors. White points were known fluoroquinolone DNA gyrase inhibitors in the training set; compounds confirmed in an in vitro assay for DNA gyrase inhibitory activity are shown in green; compounds with no in vitro activity are shown in orange. b, Examples of new DNA gyrase inhibitor chemotypes predicted by the Lasso classifier and confirmed in vitro. c, As in a, but for the mycolic acid biosynthesis inhibitor classifier applied to the mean fold change (n = 2) values from the bioactive screen. White points were known inhibitors of mycolic acid biosynthesis in the training set, with green points indicating compounds confirmed to inhibit the incorporation of 14 C-acetic acid into mycolic acid; loss-of-function KatG mutant or InhA overexpressor were resistant to compounds in blue. d, New mycolic acid biosynthesis inhibitor chemotypes predicted by the Lasso classifier and confirmed in vitro. e, As in a, but for the folate biosynthesis inhibitor classifier applied to the mean fold change (n = 2) values from the bioactive screen. White points are known inhibitors of sulfonamide folate biosynthesis in the training set; green points indicate compounds in which growth inhibitory activity was abolished by supplementation with PABA or folic acid. Compounds in which growth inhibitory activity was not abolished by PABA or folic acid supplementation are shown in orange. f, Examples of new inhibitor chemotypes of folate and tryptophan biosynthesis predicted by the Lasso classifier and confirmed by metabolite supplementation.
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Because concentrations of rifamycin in our screen inhibited all growth, their CGIPs from the primary screen were uninformative.
Taking an alternative approach, we prioritized 20 compounds that showed strong chemical-genetic interactions with the RpoB hypomorph (P < 10 −10 ), which corresponds to RNAP, and requiring it to be among the two most inhibited strains for at least one compound concentration. Testing these compounds in an in vitro RNAP assay 37, 38 , three compounds-including the antineoplastic human RNAP inhibitor actinomycin D-showed direct inhibition of the E. coli RNAP (Fig. 5a, Extended Data Fig. 8 ). Although the positive predictive value was lower than that using machine learning, PROSPECT readily identified new scaffolds against this important target, which has proved recalcitrant to whole-cell inhibitor discovery 39 .
Discovering inhibitors of a new target
Finally, we demonstrated that PROSPECT can identify inhibitors of a new target that is inaccessible to conventional strategies. Specifically, we identified a compound that inhibits the target EfpA, and optimized it to achieve potent wild-type activity.
We prioritized compounds that did not strongly inhibit wild-type Mtb, but were strongly active against at least one hypomorph at all screening concentrations. Chemically attractive scaffolds were ranked by how few hypomorphs were significantly inhibited, which was used as a proxy for specificity. The highest-ranked interaction was between BRD-8000 and the hypomorph of EfpA-an uncharacterized essential efflux pump. A broth microdilution assay confirmed that BRD-8000 was active against the EfpA hypomorph with little wild-type activity (Extended Data Fig. 9a ).
We optimized BRD-8000, first resolving the stereoisomer mixture (see Supplementary Note 7) to yield the pure active (S,S)-trans stereoisomer (BRD-8000.1; Fig. 5b ). Migration of the pyridyl bromine from the 6 to the 5 position furnished BRD-8000.2, maintaining hypomorph hypersensitivity while improving wild-type potency. Further chemical optimization yielded BRD-8000.3, a methyl-pyrazole derivative of BRD-8000.1 with an at least 60-fold overall improvement in activity from the original hit (MIC 90 = 800 nM).
BRD-8000.3 showed good mouse plasma exposure by oral dosing, and low risk for drug-drug interactions, prolongation of the QT interval, or hepatotoxicity based on minimal inhibition of cytochrome P450 enzyme activity, hERG channel binding, and cellular viability of HepG2 cells (Extended Data Fig. 9c) . Thus, BRD-8000.3 represents a good lead optimization candidate, because liabilities that typically require extensive optimization are currently absent.
The BRD-8000 series is bactericidal (Extended Data Fig. 9b 
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First, we showed that BRD-8000 inhibits efflux by EfpA uncompetitively rather than competitively-the latter being the expectation if it were a substrate being effluxed by EfpA. Specifically, we studied efflux of the known EfpA substrate ethidium bromide 41 (EtBr) in Msm, in which the pump is non-essential and thus impervious to the bactericidal effects of BRD-8000 41 (Extended Data Fig. 9e, f) . Although another known EfpA substrate, bisbenzimide-H, showed competitive inhibition of EtBr efflux in wild-type Msm, the analogues BRD-8000.2 and BRD-8000.3 showed uncompetitive inhibition (free enzyme inhibitor constant (K i )/enzyme-substrate inhibitor constant (K i ʹ) ≥ 3.3), with the trend in potency matching their corresponding MIC 90 values in Mtb (BRD-8000.2 K i ʹ = 15.9, BRD-8000.3 K i ʹ = 6.33; Table 1 ). In an efpA deletion strain of Msm (MsmΔefpA), BRD-8000.2 shows competitive inhibition (Table 1) , presumably of the low-level efflux of other, background efflux pumps.
Second, genetic evidence showed that Mtb mutants resistant to the compound all have the same amino acid substitution in EfpA. Specifically, more than 30 independent resistant Mtb mutants raised against BRD-8000.2 (resistance frequency of approximately 10 −8 ) all contained a C955A mutation in efpA, resulting in a Val319Phe substitution and conferring a more than 30-fold increase in MIC 90 (Fig. 5b) . Consistent with this mutation disrupting the compound binding site, expression of the resistant Mtb efpA V319F allele in MsmΔefpA abolished the uncompetitive inhibition by BRD-8000.2 of EtBr efflux (Table 1) .
Third, we excluded the possibility that the resistance conferred by the EfpA(V319F) mutant is due to hyperactivation of the EfpA efflux pump. There was no difference in EtBr efflux in Mtb between strains expressing wild-type EfpA and mutant EfpA(V319F), but, as expected, there was increased efflux in a Mtb strain overexpressing wild-type EfpA (Extended Data Fig. 9g ). We also measured the sensitivity of Mtb to INH, because INH resistance is known to be mediated by EfpA efflux 42, 43 ; we found no difference between Mtb strains expressing wildtype EfpA and mutant EfpA(V319F) (Extended Data Fig. 9h) . Finally, intracellular accumulation of the fluorescent analogue BRD-8000.3 was no higher in the MsmΔefpA strain expressing EfpA(V319F) versus wild-type EfpA (Extended Data Fig. 9i) .
Having confirmed that the BRD-8000 series inhibits the target EfpA, we returned to the primary screening data to identify additional EfpA inhibitors based on CGIP similarity. We tested 11 prioritized compounds for their ability to inhibit EtBr efflux and identified 3 new scaffolds, encompassing 6 molecules that inhibited EtBr efflux (Extended Data Fig. 9j-l) . Although not as specific for the EfpA efflux pump as BRD-8000, the whole-cell activity of these compounds is probably due to their activity on EfpA, because EfpA is the only essential efflux pump in Mtb 20 . Thus, the PROSPECT method can be applied iteratively to expand the chemical diversity of small-molecule candidates against a novel target quickly, even ones with unknown function.
Discussion
By enabling the discovery of many compounds against previously unexploited targets for Mtb drug development, PROSPECT is a powerful and rapid CGIP strategy. Immediate integration of potential target information empowers hit selection and prioritization by moving beyond simply compound potency. Interpreting multidimensional data guided either by the CGIPs of known compounds or by hypomorph specificity, we identified MOA for 45 new molecules. Importantly, these hits include new scaffolds against known targets-a valuable strategy to overcome antimicrobial resistance 44 -and the first inhibitors against a new target, exploiting the enormous underexplored target space in Mtb. Identifying approximately tenfold more hits than by screening wild-type Mtb alone, PROSPECT greatly expands the chemical and target space of identified compounds with the potential to reveal synergistic genetic interactions that inform the development of Mtb combination therapy.
With the discovery and optimization of an EfpA inhibitor with potent wild-type activity, we demonstrated that PROSPECT uncovers inhibitors of targets that would not have resulted from conventional approaches. Furthermore, iterative mining of the entire CGIP dataset enables the discovery of additional inhibitors of the same target. Although these large datasets have only been superficially analysed so far, we have provided examples of how integrating insight about the MOA into primary whole-cell screening can transform the targets and molecules that emerge and are prioritized, even without a clear understanding of a target's function. To accelerate the community's discovery of new inhibitor classes and their respective targets, we have made primary data publicly available (https://broad.io/cgtb). Finally, we propose that PROSPECT is widely applicable to important pathogens beyond Mtb.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-019-1315-z. To create Mtb hypomorphs, we used a protein degradation system that has been previously described 18 . In brief, a DAS+4 tag (abbreviated as DAS-tag) was recombineered into the chromosome of Mtb H37Rv, at the 3′ end of the target gene, before transformation with an ATC-inducible sspB plasmid. SspB delivers DAS-tagged protein to the native ClpXP protease. We developed plasmids that produced graded SspB induction (Extended Data Fig. 1a ) by varying the strengths of both the promoter driving transcription of sspB and the translational initiation signal required to produce SspB protein. Regulation was achieved by repression of the sspB promoter by a reverse tetracycline repressor (revTetR); we thus refer to these mutants as TetON mutants (because the presence of ATC represses degradation of the DAS-tagged target protein).
To facilitate the large scale, a sequence-design program was developed (http:// orca2.tamu.edu/tom/U19/seqtool.html). Every cassette comprises 500-basepair (bp) flanking sequences around the stop codon of the target, the DAS-tag (inserted at the 3′ end of the target gene), a loxP site, a unique nucleotide sequence ('molecular barcode'), and a hygromycin-selectable marker. If the target gene was located less than 21 bp upstream of the 5′ end of an adjacent open reading frame (ORF), a new ribosomal-binding site was inserted. Designed DNA fragments were synthesized (Gen9 or GenScript) in plasmid pUC57 with flanking PmeI sites. PmeI excision yielded double-stranded recombineering substrates 47 . Molecular barcodes enabled the identification and quantification of each strain among a pool of strains. Each barcode region was 74 nucleotides long, with common flanking regions on each end that include a PacI site (underlined) and primers for PCR amplification (capitalized), and a unique barcode sequence of 20 nucleotides (<20N>): ttaattaATCTTGTGGAAAGGACGA<20N>ACGCTATGTG GATACGCTGCTTTAattaa. Each barcode is unique to each target, thus only one SspB version strain of any target can be included in a given pool.
Strains were validated at several steps. DAS-tagged recombinants were selected by hygromycin resistance and screened for target specificity by PCR for the presence of both junctions. To confirm the presence of inserted sequence, PCR confirmation amplified the 3′ region of the targeted gene across the insert, showing increased length of the amplicon (approximately 2,500 bp), and absence of a wildtype amplicon (1,100 bp). After curing by plating recombinants on 3% sucrose, loss of the recombinase plasmid was validated by kanamycin sensitivity and by PCR screens for plasmid absence. The final step was introduction of the sspB plasmid by selection for streptomycin resistance; strains were validated by a PCR screen for the presence of the sspB plasmid.
The MsmΔefpA strain was constructed as previously described 48 . Episomal expression constructs for Mtb efpA and efpA V319F were assembled in the pUV15-tetOrm plasmid 49 , with GFP and kanamycin resistance under control of a strong, leaky ATC-inducible P smyc promoter. PCR primers were designed to linearize the pUV15 backbone, excluding the GFP-coding region, and PCR-amplified efpA from Mtb genomic DNA was inserted using the InFusion molecular cloning kit (Clontech). The Val315Phe mutation was introduced using primer-directed mutagenesis 50 . Constructs confirmed by Sanger sequencing (Eton or Genewiz) were transformed into Msm by electroporation as previously described 51 .
Multiplexed screening of compound libraries.
Bioactive compounds were identified from screening efforts in our laboratory 26, 40, 52 and previously reported in the literature [53] [54] [55] [56] , whereas the 50,000-compound library comprised Broad Institute and external collections 56 ; see also Supplementary Note 1. We optimized screening assay parameters in 384-well format, including compound exposure time (14 days), genomic DNA extraction (10% DMSO and 95 °C for 15 min), and PCR conditions (20 cycles, annealing at 65 °C) that maximized the robust Zʹ-score of log-transformed counts for a rifampin dilution series and minimized random noise as determined by strain-wise coefficient of variance. Optimal sequencing depth is discussed in Supplementary Note 2.
Final screening pool strains were grown separately in Middlebrook 7H9 (Difco) supplemented with oleic albumin dextrose catalase (OADC, from Becton Dickinson) and 10 mM sodium acetate, appropriate antibiotics, and 1 µg ml Plates were incubated for 14 days in humidified containers at 37 °C. Then, 40 µl of 10% (v/v) aqueous DMSO was added to each well, heating at 80 °C for 2 h. PCR (20 cycles) was performed in 384-well PCR plates (Eppendorf) using Q5 Master Mix (NEB) and 1 µl heat-inactivated culture in 10 µl. Primer 5′ overhangs added plate and well identification barcodes and sequences for Illumina NGS (Extended Data Fig. 1c) .
PCR products were combined and cleaned-up using AMPure XP beads (Beckmann) at twice the volume, eluting in 200 µl MilliQ water.
Sequencing was carried out at the Broad Institute Genomics Platform using Illumina HiSeq 2500 at an average sequencing depth of at least 500 reads per strain per well. Clarification of statistical analysis (http://www.R-project.org/) 57, 58 , unsupervised machine learning (https://github.com/jkrijthe/Rtsne) 36, 59, 60 , compound annotation 61 , and supervised machine learning 62 are provided in Supplementary Notes 3-6. Bactericidal compound kill kinetics. Mtb cultures at OD 600 of 0.6-1.0 were diluted to OD 600 of 0.4 and split into three 10-ml cultures. Then, 100 µl of 2.4 mM BRD-8000.2 in DMSO or 100 µl DMSO (negative control) was added to each culture, and incubated with shaking at 37 °C. At 0, 1, 2, 3, 6 and 13 days, 500-µl samples were taken from each culture, diluted 10 4 -fold, 10 5 -fold and 10 6 -fold in Middlebrook 7H9 in series and plated on Middlebrook 7H10 agar.
Agar plates were incubated at 37 °C for 21 days, before colony-forming units were counted. Broth microdilution assays. The minimum inhibitory concentration of compounds was determined in a 96-well plate (Corning), filled with 49 µl of appropriate medium (Middlebrook 7H9-OADC-acetate for Mycobacteria or Lysogeny Broth (LB) for E. coli or P. aeruginosa), and 1 µl 100× compound DMSO stock. Then, 50 µl exponential-phase bacterial culture diluted to an OD 600 of 0.005 was added. Final concentration was 0.1-50.0 µM. Plates were incubated at 37 °C in a humidified container for 24 h for non-mycobacteria, 3 days for Msm, 7 days for Mmar, and 14 days for Mtb. OD 600 was measured using a SpectraMax M5 plate reader (Molecular Dimensions). Normalized percentage outgrowth (NPO) was reported using NPO = (x i − µ n )/(µ p − µ n ), in which µ p is the mean positive control value, µ n is the mean negative control value, and x i is the value of compound i.
To determine the MBC 50 of BRD-8000.3, Mtb bacteria at OD 600 of 0.6-1.0 were washed twice with PBS containing 0.05% (w/v) tyloxapol and resuspended at a final OD 600 of 0.2 in starvation media (Middlebrook 7H9 with 0.05% (w/v) tyloxapol and no other supplementation). The carbon-starved, non-replicating drug-tolerant state was induced by incubation at 37 °C for 5 weeks 40 . Starved cultures were treated with test compounds as above, and viability was determined by plating for colony-forming units as above. DNA gyrase assays. All compounds were tested at 160 µM in duplicate in a 96-well PCR plate (Axygen). A linear pBR322 control was made via digestion of pBR322 by EcoRI-HF (NEB) for 1 h at 37 °C. Mtb DNA gyrase (Inspiralis) was diluted in 50 mM Tris-HCl at pH 7.9, 5 mM dithiothreitol (DTT), and 30% (w/v) glycerol and 2.5 U diluted DNA gyrase were added to each reaction mixture; pBR322 supercoiling and kDNA decatenation assays were carried out as recommended by the manufacturer, additionally digesting with 50 µg ml −1 proteinase K (Qiagen) before 1% (w/v) agarose gel electrophoresis. Pixel density of EtBr-stained bands was measured using ImageJ, fold change was determined by a Gamma-family generalized linear model (GLM) with a log link, using DMSO untreated control as the intercept and the relaxed band density as an offset to normalize for sample loading. Mycolic acid assay. Thin-layer chromatography detection of the incorporation of 14 C-acetic acid into mycolic acids by Mtb was carried out as previously described 63 , using 10 ml exponential-phase culture treated with 100 µl of a 100× compound stock in DMSO to give a final concentration of 10 × MIC 90 as measured by broth microdilution. Pixel density of bands was measured as above, using DMSO untreated control as the GLM intercept and the FAMEs band density as an offset to normalize for sample loading. Metabolite supplementation assay. Broth microdilution was performed as above, but each dose response series of a compound of interest was repeated three times, each time with a different metabolite in the growth medium: PABA at 200 µM from a 20 mM stock in ethanol; folic acid at 200 µM from a 20 mM stock in DMSO; and l-tryptophan at 1 mM from a 100 mM stock in 500 mM hydrochloric acid. RNA polymerase assay. Inhibition of in vitro RNA synthesis by E. coli RNAP was carried out as previously described 38 , using 2 pmol of 5′-phosphorylated, 45-nucleotide single-stranded DNA (ssDNA) oligomer (5′-GGAGCCCTTATTTA GACTTAAATAAGTTCCTCAACATCCTTCGAT-3′; Integrated DNA Technologies), which had been circularized using CircLigase ssDNA Ligase (Lucigen), E. coli RNA polymerase (NEB), 10 µM rifampin (positive control) or
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Evolution of resistant mutants. Mid-exponential growth phase bacterial cultures were pelleted and resuspended as a slurry in 1 ml Middlebrook 7H9-OADC. Then, 50 µl was plated on 6 ml agar containing 2 ×, 4 × or 8 × MIC 90 of compound. Plates were incubated at 37 °C in a humidified container for more than 21 days.
Colonies were picked and cultured in 1 ml Middlebrook 7H9-OADC-acetate in a 96-well 2 ml well volume culture block and incubated at 37 °C for 7 days in a humidified container. Whole-genome sequencing of mycobacteria. In brief, 10 µl of culture was combined with 10 µl 10% (v/v) DMSO in a 96-well clear round-bottom plate (Corning). Plates were heat-inactivated at 80 °C for 2 h. Genomic DNA (gDNA) was separated from intact cells and cell debris using AMPure XP (Beckman), eluting in 40 µl MilliQ water. gDNA (1.5 µl) was amplified using 6 µM random primers (Invitrogen) and ϕ29 DNA Polymerase (NEB) in a 10 µl reaction volume at 30 °C for 24 h.
Amplified gDNA was purified using AMPure XP and subjected to NextEra XT NGS library construction (Illumina) before 150-cycle paired-end sequencing on the Illumina MiSeq platform. Reads were aligned to the AL123456 reference sequence 64 using the BWA-mem algorithm and mutations were called using the deepSNV package 65 for R. Kinetic solubility. In brief, 10 µl of a 10 mM stock solution of test compound was added to 490 µl 50 mM phosphate buffer, pH 7.4. The solution was shaken at room temperature for 24 h, before filtering and detecting filtrate concentration using ultraviolet spectroscopy and comparing to 1, 20 and 200 µM standards. Mouse pharmacokinetics. Experiments were performed in accordance with relevant guidelines and regulations. Oral dosing of 12-h fasted female 7-9-week-old C57BL/6 mice (n = 12) was performed, using up to 150 mg kg −1 test compound in 5% (v/v) corn oil, 10% (v/v) labrasol, 5% (v/v) solutol in water. The plasma concentration of test compounds was measured at nine time points up to 8 h. Internal standard (120 µl of 100 ng ml −1 labetalol, 100 ng ml −1 dexamethasone, 100 ng ml
tolbutamide, 100 ng ml −1 verapamil, 100 ng ml −1 glyburide, 100 ng ml −1 celecoxib in acetonitrile) was added to 6 µl plasma samples. Protein precipitate was centrifuged out; 4 µl supernatant was subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, on a UPLC protein BEH C4 1.7 µm 2.1 × 50 mm column (Acquity) with gradient of 22-95% acetonitrile in water, and detecting using a positive-mode Triple Quad 6500+ mass spectrometer (AB SCIEX Instruments). HepG2 toxicity. HepG2 cells (50 µl) were seeded at a density of 1,000 cells per well. Test compounds dissolved in DMSO were threefold serially diluted for ten doses (n = 1). Compound stocks (125 nl) were transferred into a 384-well plate, which was incubated for 72 h at 37 °C. The plate was allowed to reach room temperature for 30 min, after which 25 µl CellTiterGlo reagent (Promega) was added. After 10 min, luminescence was detected using an EnVision platereader (PerkinElmer). Normalized percentage inhibition was calculated using DMSO vehicle control values, and 1 µM paclitaxel. The half-maximum inhibitory concentration (IC 50 ) values were calculated using the four-parameter logistic model in Prism statistical analysis software (GraphPad). Microsomal stability. Test compound (1 µM) was incubated with pooled microsomes in 100 mM potassium phosphate buffer, pH 7.4, supplemented with 2 mM NADPH and 3 mM magnesium chloride at 37 °C. At 0, 5, 15, 30 and 45 min, samples were taken (n = 1), and stopped by adding an equal volume ice-cold methanol, and incubating on ice for 10 min. After removing precipitated protein by centrifugation, remaining compound was measured using LC-MS/MS as above. Half-life was determined by fitting a first-order decay model to the time course. Isoform-specific cytochrome P450 (CYP) inhibition. Seven concentrations (n = 1) of test compound, of which the DMSO stock solution was diluted tenfold in acetonitrile, were added to pooled human liver microsomes in 100 mM potassium phosphate buffer, pH 7.4, supplemented with 2 mM NADPH and 3 mM magnesium chloride at 37 °C. Conversion of isoform-specific substrate probes to their products (tacrine to hydroxytacrine for CYP1A2; bupropion to hydroxybupropion for CYP2B6; amodiaquine to desethylamodiaquine for CYP2C8; tolbutamide to α-hydroxytolbutamide for CYP2C9; mephenyltoin to 4-hydroxymephenyltoin for CYP2C19; and dextromethorphan to dextrorphan for CYP2D6) was stopped after 10 min incubation (15 min for CYP2C9; 60 min for CYP2C19) by adding an equal volume of methanol, and incubating on ice for 10 min. After removing precipitated protein by centrifugation, products were measured using LC-MS/ MS. Reduction in substrate conversion was normalized to the maximal effects of isoform-specific positive controls (α-naphthoflavone for CYP1A2; ticlopidine for CYP2B6; quercetin for CYP2C8; sulfaphenazole for CYP2C9; ticlopidine for CYP2C19;, and quinidine for CYP2D6). Mouse plasma protein binding. Protein-free and plasma protein-containing compartments were separated with a semi-permeable membrane, and allowed to equilibrate with 5 µM test compound at 37 °C (n = 3). Compound concentration on both sides of the membrane was measured using LC-MS/MS, and the bound fraction was calculated as 1 − F c /T c , in which F c is the free compound concentration in the dialysate, and T c is the compound concentration in the retentate. Warfarin was used as a positive control. hERG inhibition. hERG inhibition (n = 2) was assayed using the Predictor hERG Fluorescence Polarization Kit (Thermo) according to the manufacturer's instructions. Efflux assay. Efflux rates were measured as previously described [66] [67] [68] . Msm or Mtb strains were grown in Middlebrook 7H9 medium to an OD 600 of 0.4-0.6. Cultures were then centrifuged for 5 min at 3,500 r.p.m. The pellet was washed once with PBS at 37 °C and resuspended in PBS to give a final OD 600 of 0.4. Cultures were split into eight and EtBr (or bisbenzimide-H) was added at a final concentration of 0.2-1.95 µg ml −1 (or for bisbenzimide-H, 0.6-6.3 µg ml −1
), and bacteria were incubated for 30 min (Msm) or 2 h (Mtb) at 37 °C. After EtBr treatment, cells were centrifuged for 5 min at 3,500 r.p.m. and resuspended in 37 °C PBS to give a final OD 600 of 0.8. A white 96-well plate (Corning) was prepared with serially diluted compound and 50 µl PBS containing 0.8% (w/v) glucose. Dye-loaded bacteria (50 µl) were added to each well of the plate. Fluorescence was read at 37 °C in a SpectraMax M5 plate reader using 530 nm excitation and 585 nm emission wavelengths for EtBr (or 346 nm and 460 nm for bisbenzimide-H) and was recorded every 30 s for 2 h (Msm) or 4 h (Mtb).
To infer kinetic parameters, we modelled the rate of fluorescence decay as a modified Michaelis-Menten 67 equation, which included a term for Fick diffusion 69 between the cytoplasm and extracellular milieu. This approach is discussed in Supplementary Note 8.
Compound accumulation assay. Accumulation of BRD-8000.3 inside Msm bacteria was assayed in triplicate as previously described 70 , using the intrinsic fluorescence of the compound in PBS containing 0.4% (w/v) glucose, and 1.5 µl of 5 mM BRD-8000.3 in DMSO. Bacteria were then incubated for 3 h at 37 °C. Suspensions were centrifuged for 10 min at 3,500 r.p.m. Cell pellets were resuspended in 60 µl PBS containing 5% (v/v) DMSO then frozen at −80 °C for 20 min, heated to 98 °C for 15 min, before centrifugation at 10,000 r.p.m. for 10 min.
Lysate (60 µl) was added to wells of a black 384-well plate. Excitation and emission wavelengths of BRD-8000.3 were 355 nm and 419 nm. Change in compound accumulation in lysate was determined by subtracting mean untreated control fluorescence from the treated sample fluorescence. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
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